Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Testa tillägget av lenalidomid och nivolumab till den vanliga behandlingen för primärt CNS-lymfom

16 november 2026 uppdaterad av: National Cancer Institute (NCI)

Fas I-studie av metotrexat, rituximab, lenalidomid och nivolumab (Nivo-MR2) induktion följt av lenalidomid och nivolumab underhåll vid primärt CNS-lymfom

This phase I trial tests the safety, side effects, best dose and effectiveness of lenalidomide when added to nivolumab and the usual drugs (rituximab and methotrexate) in patients with primary central nervous system (CNS) lymphoma. Lenalidomide may stop or slow primary CNS lymphoma by blocking the growth of new blood vessels necessary for tumor growth. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of cancer cells to grow and spread. Rituximab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Methotrexate is frequently combined with other chemotherapy agents to improve response. This study may help increase the understanding of lenalidomide and nivolumab use in primary CNS lymphoma treatment. In addition, it may help researchers see whether the control of CNS lymphoma can be extended by using these study drugs as maintenance (prolonged therapy) after control is achieved with the initial chemotherapy regimen (induction).

Studieöversikt

Detaljerad beskrivning

PRIMARY OBJECTIVES:

I. Determine the maximum tolerated dose (MTD) of lenalidomide when given in combination with high dose-methotrexate (HD-MTX) and rituximab, with or without nivolumab, as induction treatment of primary CNS lymphoma.

II. Determine the proportion of patients who are able to stay on maintenance therapy with lenalidomide and/or nivolumab for 6 months after induction treatment of primary CNS lymphoma.

SECONDARY OBJECTIVES:

I. To evaluate the overall response rate (ORR) of the combination of methotrexate, rituximab, lenalidomide, nivolumab.

II. To evaluate the effect of the treatment regimen and lenalidomide / nivolumab maintenance on progression free survival (PFS).

III. To evaluate the effect of the treatment regimen and lenalidomide / nivolumab maintenance on overall survival (OS).

EXPLORATORY OBJECTIVES:

I. To analyze tumor tissue and cerebrospinal fluid (CSF) for gene expression profiles, and to correlate these profiles with treatment outcomes.

II. To determine whether CSF proteome and metabolome are predictors of outcomes (prognostic marker).

III. To assess response to therapy and minimal residual disease via MRI-based metrics and minimal residual disease of blood and CSF.

IV. To evaluate the relationship between neurocognitive deficits and tumor and brain volumetrics, as assessed by magnetic resonance imaging (MRI) and tumor metabolism.

OUTLINE: This is a dose-escalation study of lenalidomide.

INDUCTION: Patients receive rituximab intravenously (IV) on day 1, methotrexate IV over 2 hours or orally (PO) on day 2, lenalidomide PO daily on days 5-9, and nivolumab IV over 30 minutes on day 14. (In dose level IV that includes nivolumab, the doses of rituximab for cycles 2-6 may be given on the same day as nivolumab for the previous cycle). Treatment repeats every 14 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients who achieve complete response, partial response, or stable disease proceed to maintenance therapy.

MAINTENANCE: Within 6 weeks after the last dose of lenalidomide in induction therapy, patients receive lenalidomide PO daily on days 1-21, and nivolumab IV over 30 minutes on day 1. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.

Patients also undergo magnetic resonance imaging (MRI) throughout the trial, computed tomography (CT) and positron emission tomography (PET)/CT during screening, and lumbar puncture at the end of the 6th cycle of induction, and after 6 months of maintenance. Patients may also undergo bone marrow aspirate and biopsy, testicular ultrasound and/or echocardiogram (ECHO) during screening.

After completion of study treatment, patients are followed up every 3 months for 2 years, then every 6 months for up to 2 years.

Studietyp

Interventionell

Inskrivning (Beräknad)

47

Fas

  • Fas 1

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

    • California
      • Los Angeles, California, Förenta staterna, 90048
        • Cedars-Sinai Medical Center
      • San Francisco, California, Förenta staterna, 94143
        • UCSF Medical Center-Parnassus
    • Florida
      • Coral Gables, Florida, Förenta staterna, 33146
        • UM Sylvester Comprehensive Cancer Center at Coral Gables
      • Deerfield Beach, Florida, Förenta staterna, 33442
        • UM Sylvester Comprehensive Cancer Center at Deerfield Beach
      • Doral, Florida, Förenta staterna, 33166
        • UM Sylvester Comprehensive Cancer Center at Doral
      • Miami, Florida, Förenta staterna, 33136
        • University of Miami Miller School of Medicine-Sylvester Cancer Center
      • Miami, Florida, Förenta staterna, 33176
        • UM Sylvester Comprehensive Cancer Center at Kendall
      • North Miami, Florida, Förenta staterna, 33181
        • University of Miami Sylvester Comprehensive Cancer Center at Sole Mia
      • Plantation, Florida, Förenta staterna, 33324
        • UM Sylvester Comprehensive Cancer Center at Plantation
    • Iowa
      • Ankeny, Iowa, Förenta staterna, 50023
        • UI Health Care Mission Cancer and Blood - Ankeny Clinic
      • Carroll, Iowa, Förenta staterna, 51401
        • Saint Anthony Regional Hospital
      • Clive, Iowa, Förenta staterna, 50325
        • UI Health Care Mission Cancer and Blood - West Des Moines Clinic
      • Des Moines, Iowa, Förenta staterna, 50309
        • Iowa Methodist Medical Center
      • Des Moines, Iowa, Förenta staterna, 50314
        • Mercy Medical Center - Des Moines
      • Des Moines, Iowa, Förenta staterna, 50314
        • Broadlawns Medical Center
      • Des Moines, Iowa, Förenta staterna, 50316
        • Iowa Lutheran Hospital
      • Des Moines, Iowa, Förenta staterna, 50309
        • UI Health Care Mission Cancer and Blood - Des Moines Clinic
      • Des Moines, Iowa, Förenta staterna, 50314
        • UI Health Care Mission Cancer and Blood - Laurel Clinic
      • Fort Dodge, Iowa, Förenta staterna, 50501
        • UI Healthcare Mission Cancer and Blood - Fort Dodge
      • Iowa City, Iowa, Förenta staterna, 52242
        • University of Iowa/Holden Comprehensive Cancer Center
      • Waukee, Iowa, Förenta staterna, 50263
        • UI Health Care Mission Cancer and Blood - Waukee Clinic
      • West Des Moines, Iowa, Förenta staterna, 50266-7700
        • Methodist West Hospital
    • Louisiana
      • Baton Rouge, Louisiana, Förenta staterna, 70805
        • LSU Health Baton Rouge-North Clinic
      • Baton Rouge, Louisiana, Förenta staterna, 70808
        • Our Lady of the Lake Physician Group
    • Maine
      • Portland, Maine, Förenta staterna, 04102
        • MaineHealth Maine Medical Center - Portland
      • Scarborough, Maine, Förenta staterna, 04074
        • MaineHealth Maine Medical Center- Scarborough
      • South Portland, Maine, Förenta staterna, 04106
        • MaineHealth Cancer Care and IV Therapy - South Portland
    • Michigan
      • Adrian, Michigan, Förenta staterna, 49221
        • Hickman Cancer Center
      • Monroe, Michigan, Förenta staterna, 48162
        • Toledo Clinic Cancer Centers-Monroe
    • Missouri
      • City of Saint Peters, Missouri, Förenta staterna, 63376
        • Siteman Cancer Center at Saint Peters Hospital
      • Creve Coeur, Missouri, Förenta staterna, 63141
        • Siteman Cancer Center at West County Hospital
      • St Louis, Missouri, Förenta staterna, 63110
        • Washington University School of Medicine
      • St Louis, Missouri, Förenta staterna, 63129
        • Siteman Cancer Center-South County
      • St Louis, Missouri, Förenta staterna, 63136
        • Siteman Cancer Center at Christian Hospital
    • New Jersey
      • Summit, New Jersey, Förenta staterna, 07902
        • Overlook Hospital
    • New York
      • Lake Success, New York, Förenta staterna, 11042
        • Northwell Health/Center for Advanced Medicine
      • Manhasset, New York, Förenta staterna, 11030
        • North Shore University Hospital
      • New York, New York, Förenta staterna, 10032
        • NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
      • New York, New York, Förenta staterna, 10065
        • NYP/Weill Cornell Medical Center
      • Syracuse, New York, Förenta staterna, 13210
        • State University of New York Upstate Medical University
    • North Carolina
      • Chapel Hill, North Carolina, Förenta staterna, 27599
        • UNC Lineberger Comprehensive Cancer Center
    • Ohio
      • Columbus, Ohio, Förenta staterna, 43210
        • Ohio State University Comprehensive Cancer Center
      • Toledo, Ohio, Förenta staterna, 43623
        • Toledo Clinic Cancer Centers-Toledo
    • Oklahoma
      • Oklahoma City, Oklahoma, Förenta staterna, 73104
        • University of Oklahoma Health Sciences Center
    • Rhode Island
      • Providence, Rhode Island, Förenta staterna, 02903
        • Rhode Island Hospital
    • South Carolina
      • Charleston, South Carolina, Förenta staterna, 29425
        • Medical University of South Carolina
    • Texas
      • Dallas, Texas, Förenta staterna, 75390
        • UT Southwestern/Simmons Cancer Center-Dallas
    • Utah
      • Salt Lake City, Utah, Förenta staterna, 84112
        • Huntsman Cancer Institute/University of Utah
    • West Virginia
      • Morgantown, West Virginia, Förenta staterna, 26506
        • West Virginia University Healthcare
    • Wisconsin
      • Eau Claire, Wisconsin, Förenta staterna, 54701
        • Marshfield Medical Center-EC Cancer Center
      • La Crosse, Wisconsin, Förenta staterna, 54601
        • Gundersen Lutheran Medical Center
      • Marshfield, Wisconsin, Förenta staterna, 54449
        • Marshfield Medical Center-Marshfield
      • Minocqua, Wisconsin, Förenta staterna, 54548
        • Marshfield Medical Center - Minocqua
      • Rice Lake, Wisconsin, Förenta staterna, 54868
        • Marshfield Medical Center-Rice Lake
      • Stevens Point, Wisconsin, Förenta staterna, 54482
        • Marshfield Medical Center-River Region at Stevens Point
      • Weston, Wisconsin, Förenta staterna, 54476
        • Marshfield Medical Center - Weston

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  • Histologically proven primary CNS diffuse large b-cell lymphoma confirmed by one of the following:

    • Brain biopsy or resection
    • Cerebrospinal fluid
    • Vitreous fluid
  • No prior organ transplantation to exclude post-transplant lymphoproliferative disorders

  • No prior chemotherapy or radiation therapy for lymphoma

  • No prior allogeneic stem cell transplantation

  • Use of systemic corticosteroids (dexamethasone up to 24 mg/day or equivalent) for disease control or improvement of performance status to be tapered as fast as clinically safe after initiation of therapy is permissible

  • Not pregnant and not nursing, because this study involves an investigational agent whose genotoxic, mutagenic and teratogenic effects on the developing fetus and newborn are unknown and an agent that has known genotoxic, mutagenic and teratogenic effects. Therefore, female of childbearing potential (FCBP) must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin [HCG]) =< 7 days prior to registration

  • Age >= 18 years

  • Karnofsky performance scale (KPS) >= 40 (>= 50 for patients older than 60 unless related to lymphoma on investigator's opinion)

  • Absolute neutrophil count (ANC) >= 1,500/mm^3

  • Platelet count >= 100,000/mm^3

  • Calculated (calc.) creatinine clearance >= 50 mL/min by Cockcroft-Gault formula

  • Total Bilirubin =< 1.5 x upper limit of normal (ULN)

  • Aspartate aminotransferase (AST) / alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN)

  • No evidence of non-Hodgkin's lymphoma (NHL) outside CNS

  • No prior history of NHL

  • No history of autoimmune disorder. Patients with active autoimmune disease or history of autoimmune disease that might recur, which may affect vital organ function or require immune suppressive treatment including systemic corticosteroids, should be excluded. These include but are not limited to patients with a history of immune related neurologic disease, multiple sclerosis, autoimmune (demyelinating) neuropathy, Guillain-Barre syndrome, myasthenia gravis; systemic autoimmune disease such as Systemic lupus erythematosus (SLE), connective tissue diseases, scleroderma, inflammatory bowel disease (IBD), Crohn's, ulcerative colitis, hepatitis; and patients with a history of toxic epidermal necrolysis (TEN), Stevens-Johnson syndrome, or phospholipid syndrome should be excluded because of the risk of recurrence or exacerbation of disease. Patients with vitiligo, endocrine deficiencies including thyroiditis managed with replacement hormones including physiologic corticosteroids are eligible. Patients with rheumatoid arthritis and other arthropathies, Sjogren's syndrome and psoriasis controlled with topical medication and patients with positive serology, such as antinuclear antibodies (ANA), anti-thyroid antibodies should be evaluated for the presence of target organ involvement and potential need for systemic treatment but should otherwise be eligible

  • Patients are permitted to enroll if they have vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger (precipitating event)

  • Patients should be excluded if they have a condition requiring systemic treatment with either corticosteroids (except short course of systemic corticosteroids for disease control or improvement of performance status) or other immunosuppressive medications within 14 days prior to registration. Inhaled or topical steroids and adrenal replacement doses < 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease. Patients are permitted to use topical, ocular, intra-articular, intranasal, and inhalational corticosteroids (with minimal systemic absorption). Physiologic replacement doses of systemic corticosteroids are permitted, even if < 10 mg/day prednisone equivalents. A brief course of corticosteroids for prophylaxis (e.g., contrast dye allergy) or for treatment of non-autoimmune conditions (e.g., delayed-type hypersensitivity reaction caused by contact allergen) is permitted

  • Patients who have had evidence of active or acute diverticulitis, intra-abdominal abscess, gastrointestinal (GI) obstruction and abdominal carcinomatosis which are known risk factors for bowel perforation should be evaluated for the potential need for additional treatment before coming on study

  • No prior or concurrent malignancies with exception of surgically cured carcinoma in situ (CIS) of the uterus, carcinoma of the skin without evidence of disease for >= 5 years

  • No concurrent malignancy requiring active therapy

  • No untreated hepatitis C virus (HCV) infection with detectable HCV viral load

  • No untreated chronic hepatitis B virus (HBV) infection with detectable HBV viral load

  • No untreated human immunodeficiency virus (HIV) infection or with detectable viral load or with CD4+T-cell count of less than 500/mm^3

  • No history of HIV infection and evidence of Epstein Barr virus (EBV)-related primary central nervous system lymphoma (PCNSL)

  • Inability to tolerate anticoagulation with acetylsalicylic acid, warfarin, or direct oral anticoagulants

  • No other investigational agent

  • No history of severe hypersensitivity reaction to any monoclonal antibody

  • No history of allergic reactions attributed to compounds of similar chemical or biologic composition to or other agents used in study

  • Sulfonamide drugs, trimethoprim, salicylates, nonsteroidal anti-inflammatory drugs, penicillin, vitamin C, ciprofloxacin, and proton pump inhibitors should be held at least 48 hours prior to methotrexate administration

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: N/A
  • Interventionsmodell: Enskild gruppuppgift
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Treatment (rituximab, methotrexate, lenalidomide, nivolumab)

INDUCTION: Patients receive rituximab IV on day 1, methotrexate IV over 2 hours or PO on day 2, lenalidomide PO daily on days 5-9, and nivolumab IV over 30 minutes on day 14. (In dose level IV that includes nivolumab, the doses of rituximab for cycles 2-6 may be given on the same day as nivolumab for the previous cycle). Treatment repeats every 14 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients who achieve complete response, partial response, or stable disease proceed to maintenance therapy.

MAINTENANCE: Within 6 weeks after the last dose of lenalidomide in induction therapy, patients receive lenalidomide PO daily on days 1-21, and nivolumab IV over 30 minutes on day 1. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.

Patients also undergo MRI, CT, PET/CT, lumbar puncture, bone marrow aspirate and biopsy, testicular ultrasound and ECHO. (See Detailed Description)

Given PO

Andra namn:
  • CC-5013
  • Revlimid
  • CC5013
  • CDC 501
  • CC 5013

Given IV

Andra namn:
  • Rituxan
  • MabThera
  • ABP 798
  • BI 695500
  • C2B8 monoklonal antikropp
  • Chimär anti-CD20-antikropp
  • CT-P10
  • IDEC-102
  • IDEC-C2B8
  • IDEC-C2B8 monoklonal antikropp
  • Monoklonal antikropp IDEC-C2B8
  • PF-05280586
  • Riabni
  • Rituximab ABBS
  • Rituximab ARRX
  • Rituximab Biosimilar ABP 798
  • Rituximab Biosimilar BI 695500
  • Rituximab Biosimilar CT-P10
  • Rituximab Biosimilar GB241
  • Rituximab Biosimilar IBI301
  • Rituximab Biosimilar JHL1101
  • Rituximab Biosimilar PF-05280586
  • Rituximab Biosimilar RTXM83
  • Rituximab Biosimilar SAIT101
  • Rituximab Biosimilar SIBP-02
  • rituximab biosimilar TQB2303
  • Rituximab PVVR
  • Rituximab-arrx
  • Rituximab-pvvr
  • RTXM83
  • Ruxience
  • Truxima
  • Rixathon
  • Ikgdar
  • Mabtas
  • Rituximab-abbs
  • BI-695500
  • BI695500
  • Blitzima
  • IDEC 102
  • IDEC102
  • PF 05280586
  • PF05280586
  • Ritemvia
  • Rituximab-blit
  • Rituximab-rit
  • Rituximab-rixa
  • Rituximab-rixi
  • Riximyo
  • RTXM 83
  • RTXM-83
  • ABP-798
  • ABP798
  • CT P10
  • CTP10
  • GP 2013
  • GP-2013
  • GP2013
  • Rituximab Biosimilar GP2013

Undergo MRI

Andra namn:
  • MRI
  • Magnetisk resonans
  • Magnetic Resonance Imaging Scan
  • Medicinsk bildbehandling, magnetisk resonans / kärnmagnetisk resonans
  • HERR
  • MR-avbildning
  • MRI-skanning
  • NMR-avbildning
  • NMRI
  • Kärnmagnetisk resonanstomografi
  • Magnetisk resonanstomografi (MRT)
  • sMRI
  • Magnetisk resonanstomografi (förfarande)
  • Strukturell MRI

Undergo ECHO

Andra namn:
  • Ekokardiografi
  • EC

Given IV

Andra namn:
  • BMS-936558
  • MDX-1106
  • NIVO
  • ONO-4538
  • Opdivo
  • CMAB819
  • Nivolumab Biosimilar CMAB819
  • MDX 1106
  • MDX1106
  • BMS 936558
  • ABP 206
  • Nivolumab Biosimilar ABP 206
  • BCD-263
  • Nivolumab Biosimilar BCD-263
  • BMS936558
  • ONO 4538
  • ONO4538

Undergo lumbar puncture

Andra namn:
  • LP
  • Spinal Tap

Undergo PET/CT

Andra namn:
  • Medicinsk avbildning, Positron Emission Tomografi
  • SÄLLSKAPSDJUR
  • Djur Scan
  • Positron Emission Tomography Scan
  • Positronemissionstomografi
  • PT
  • Positronemissionstomografi (förfarande)

Undergo CT and PET/CT

Andra namn:
  • CT
  • KATT
  • Datortomografi
  • Beräknad axiell tomografi
  • Datoriserad axialtomografi
  • tomografi
  • Datoriserad axiell tomografi (förfarande)
  • Datortomografi (CT) skanning
  • Diagnostisk kattskanning
  • Diagnostisk kattskanningstjänsttyp

Undergo bone marrow aspirate and biopsy

Given IV or PO

Andra namn:
  • Abitrexat
  • Folex
  • Mexate
  • MTX
  • Alfa-metopterin
  • Ametopterin
  • Brimexat
  • CL 14377
  • CL-14377
  • Emtexat
  • Emthexat
  • Farmitrexat
  • Fauldexato
  • Folex PFS
  • Lantarel
  • Ledertrexat
  • Lumexon
  • Maxtrex
  • Medsatrexat
  • Metex
  • Metoblastin
  • Metotrexat LPF
  • Metotrexat Metylaminopterin
  • Metotrexatum
  • Metotrexato
  • Metrotex
  • Mexate-AQ
  • Novatrex
  • Reumatrex
  • Texate
  • Tremetex
  • Trexeron
  • Trixilem
  • WR-19039
  • Jylamvo

Undergo testicular ultrasound

Andra namn:
  • Ultraljud
  • 2-dimensionell ultraljudsavbildning i gråskala
  • 2-dimensionell ultraljudsavbildning
  • 2D-US
  • Ultraljudstest
  • Ultraljud, medicinsk
  • USA

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Maximum tolerated dose
Tidsram: During the first 14-day cycle of treatment

Defined as the dose level below the lowest dose that induces dose-limiting toxicity in at least one-third of patients (at least 2 of a maximum of 6 new patients). The number and severity of all adverse events will be tabulated and summarized in this patient population both overall and by dose level according to the Common Terminology Criteria for Adverse Events (CTCAE) Cancer Therapy Evaluation Program version 5.0 criteria. The grade 3+ adverse events will also be described and summarized in a similar fashion. This will provide an indication of the level of tolerance for this treatment combination in this patient group.

During the first 14-day cycle of treatment
Proportion of evaluable patients who are able to stay on maintenance therapy
Tidsram: Up to 6 months

The proportion of evaluable patients who meet the criteria for maintenance feasibility, along with the 95% exact binomial confidence interval, will be provided.

Up to 6 months

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Overall response
Tidsram: Up to 5 years

Will be estimated by the number of patients with the objective status of complete response, unconfirmed complete response, or partial response divided by the total number of evaluable patients. The overall response rate with an exact binomial 95% confidence interval will be provided and will be analyzed at the end of induction therapy and again after all therapy (induction and maintenance).

Up to 5 years
Progression free survival (PFS)
Tidsram: Time from start of induction treatment to progression or death due to any cause

The distribution of progression-free survival will be estimated using the method of Kaplan-Meier (Kaplan-Meier, 1958). PFS time from start of maintenance therapy will also be reported in a similar fashion as the PFS time starting from induction therapy.

Time from start of induction treatment to progression or death due to any cause
Overall Survival (OS)
Tidsram: Time from start of induction treatment to death due to any cause

The distribution of overall survival will be estimated using the method of Kaplan-Meier (Kaplan-Meier, 1958). OS time from start of maintenance therapy will also be reported in a similar fashion as the OS time starting from induction therapy.

Time from start of induction treatment to death due to any cause
Incidence of adverse events
Tidsram: Up to 5 years

Toxicity will be measured by the CTCAE version 5.0. The maximum grade, frequency, and severity for each type of adverse event will be recorded for each patient, and frequency tables will be reviewed to determine patterns. Additionally, the relationship of the adverse event(s) to the study treatment will be taken into consideration and analyzed descriptively.

Up to 5 years

Andra resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Minimal residual disease (MRD)
Tidsram: Up to 5 years

Will estimate the proportion of patients with MRD at each time point with 95% confidence intervals. Will also use swimmer plots and other graphical analyses to visualize when MRD is detected/not detected in sequential samples relative to progression of disease.

Up to 5 years

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Huvudutredare: Alvaro J Alencar, Alliance for Clinical Trials in Oncology

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

24 maj 2021

Primärt slutförande (Beräknad)

1 augusti 2027

Avslutad studie (Beräknad)

1 augusti 2027

Studieregistreringsdatum

Först inskickad

29 oktober 2020

Först inskickad som uppfyllde QC-kriterierna

29 oktober 2020

Första postat (Faktisk)

30 oktober 2020

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

18 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

16 november 2026

Senast verifierad

1 oktober 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

JA

IPD-planbeskrivning

NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Ja

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

produkt tillverkad i och exporterad från U.S.A.

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera